Nanjing Nuoyuan Medical Devices Co. Ltd. has discovered drug conjugates comprising a fluorescent moiety targeting hepatocyte growth factor receptors (HGFR; MET) covalently linked to crizotinib through a linker. They are reported to be useful for diagnosis of liver and colon cancer.
Asieris Pharmaceuticals Co. Ltd. has identified compounds acting as inhibitors of CDK1/cyclin A2, CDK2/cyclin E1, CDK4/cyclin D1 and CDK6/cyclin D1 reported to be useful for the treatment of breast and ovary cancer.
Perseus Proteomics Inc. and Ube Corp. have disclosed antibody-drug conjugates (ADCs) comprising antibodies T004b-PGAP-1 targeting human P-cadherin (CDH3) targeting covalently linked to cytotoxic drug through a linker reported to be useful for the treatment of cancer.
Weatherwax Biotechnologies Corp. has prepared and tested cellular tumor antigen p53 (TP53) (Y220C mutant) activators reported to be useful for the treatment of cancer.
Akari Therapeutics plc has released preclinical data demonstrating the potential of its novel antibody-drug conjugate (ADC) spliceosome modulating payload, PH1, for the treatment of tumors driven by alternative splicing-drivers, such as the androgen receptor splice variant 7 (AR-V7) in prostate cancer.
Amphista Therapeutics Ltd. has disclosed first data on its TEAD oncology therapeutic program. The company’s TEAD Targeted Glues are inherently smaller and more drug-like molecules than conventional PROTAC binders.
The oncofetal antigen 5T4 is a cell surface glycoprotein overexpressed in many solid tumors, while its expression in normal tissues is limited, making it an attractive target for cancer therapies. Its association with tumor progression and poor prognosis further supports its therapeutic potential.
Clarivate plc has unveiled the 2025 Citation Laureates. Widely considered a predictor of the Nobel Prizes, this recognition has highlighted the discovery of biomolecular condensates in chemistry and the innate immunity signaling pathway in physiology or medicine, as well as the identification of leukemia stem cells and ghrelin, the so-called hunger hormone.
China Pharmaceutical University has patented non-ubiquitin proteolysis targeting chimera (NuTACs) comprising proteasomal ubiquitin receptor ADRM1 (ARM1; hRpn13) linked to programmed cell death 1 ligand 1 (CD274; PD-L1) and/or bromodomain-containing protein 4 (BRD4; HUNK1)-targeting moiety. They are reported to be useful for the treatment of cancer, eye disorders, viral infections, autoimmune diseases, inflammatory disorders and systemic inflammatory response syndrome.
3B Pharmaceuticals GmbH has discovered conjugates comprising peptides targeting urokinase plasminogen activator surface receptor (uPAR) covalently linked to a chelating moiety through a linker. They are reported to be useful for the diagnosis and/or treatment of cancer.
RSS
